Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06598371 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
A Phase 1 study of Select Advanced Solid Tumors, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 141
- Enrollment target
- 1
- Study location
NCT06598371 is a Phase 1 study of Select Advanced Solid Tumors that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 141 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06598371, a Phase 1 study of Select Advanced Solid Tumors, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 141 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase 1 is to find the recommended dose of KSQ-004EX to give to participants with advanced solid tumors. Phase 2 is to learn if KSQ-004EX at the recommended dose found in Phase1 can help to control advanced solid tumors. The safety and effects of KSQ-004EX will also be studied in both phases.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Interleukin-2
- DRUG KSQ-004EX
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2024-11-21 |
| Est. Completion | 2041-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06598371
The ClinicalTrials.gov registry entry for NCT06598371 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Select Advanced Solid Tumors appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT06598371 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06598371 about?
NCT06598371 is a clinical study titled "A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors". Phase 1 is to find the recommended dose of KSQ-004EX to give to participants with advanced solid tumors. Phase 2 is to learn if KSQ-004EX at the recommended dose found in Phase1 can help to control advanced solid tumors. The safety and effects of KSQ-004EX will also be studied in both phases.
What is the current status of trial NCT06598371?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 141 participants. The study started on 2024-11-21. Estimated completion is 2041-08-01.
What conditions does trial NCT06598371 study?
This clinical trial studies the following conditions: Select Advanced Solid Tumors.
What interventions are being tested in trial NCT06598371?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Interleukin-2 (DRUG), KSQ-004EX (DRUG).
Who is sponsoring clinical trial NCT06598371?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06598371 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Select Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.